About
Tarsier Pharma Ltd.
Tarsier Pharma is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet need in blinding diseases of the eye with underlying inflammatory pathologies.
Our dazdotuftide platform technology is a bio-inspired immunomodulator, designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops (TRS01) and intravitreal injections (TRS02).
The data for this page was gathered manually by the Stock Analysis team, from official company filings available on SEC.gov.
Tarsier Pharma Ltd. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Profitability & Returns
Margins and return on capital
Financial Highlights
Historical financial performance
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| F-1/A | Jun 16, 2026 | [Amend] Registration statement for certain foreign private issuers |
| F-1/A | Jun 8, 2026 | [Amend] Registration statement for certain foreign private issuers |
| FWP | May 18, 2026 | Free Writing Prospectus |
| F-1/A | May 18, 2026 | [Amend] Registration statement for certain foreign private issuers |
| F-1 | Apr 21, 2026 | Registration statement for certain foreign private issuers |
| DRS/A | Mar 31, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS/A | Feb 24, 2026 | [Amend] [Cover] Draft Registration Statement |
| DRS | Dec 29, 2025 | [Cover] Draft Registration Statement |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Daphne Haim-Langford, Ph.D.
Chief Executive Officer and Chairperson of the Board
Arie Ganot, CPA
Chief Financial Officer
Zohar Milman, M.Sc.
Chief Operating Officer
Ron Neumann, M.D.
Chief Medical Officer
Susan Benton
Director
Sascha Bucher
Director
Atul Raut
Director
